Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E.R. Parra, V. Capelozzi (Sao Paulo, Brazil). Hyaluroman syntehase-2 over expression has impact in the evolution and on the prognosis of idiopathic pulmonary fibrosis patients. Eur Respir J 2012; 40: Suppl. 56, 3154

Member's Comments

No comment yet.

Related content which might interest you: Is age a predictor in prognosis of patients with idiopathic pulmonary fibrosis? Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Comparison of clinical characteristics and prognosis in patients with idiopathic pulmonary upper lobe predominant pulmonary fibrosis and idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 The influence of smoking history on the prognosis of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Genetic predictors of idiopathic pulmonary fibrosis (IPF) prognosis Source: Eur Respir J 2006; 28: Suppl. 50, 830s Year: 2006 The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (1) 1700379; 10.1183/13993003.00379-2017 Year: 2017 Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Towards a better diagnosis of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 108-113 Year: 2011 Pulmoanry hypertension is a negative prognostic factot of long term survival in patients with idiopathic pulmonary fibrosis after lung transplantation Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 PD-L1 expression in patients with idiopathic pulmonary fibrosis. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020 Year: 2020 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016 Year: 2017 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 373s Year: 2007